A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
- Supplementary File 1:
PDF-Document (PDF, 997 KiB)
Ragan, I.K.; Hartson, L.M.; Dutt, T.S.; Obregon-Henao, A.; Maison, R.M.; Gordy, P.; Fox, A.; Karger, B.R.; Cross, S.T.; Kapuscinski, M.L.; Cooper, S.K.; Podell, B.K.; Stenglein, M.D.; Bowen, R.A.; Henao-Tamayo, M.; Goodrich, R.P. A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model. Vaccines 2021, 9, 340. https://doi.org/10.3390/vaccines9040340
Ragan IK, Hartson LM, Dutt TS, Obregon-Henao A, Maison RM, Gordy P, Fox A, Karger BR, Cross ST, Kapuscinski ML, Cooper SK, Podell BK, Stenglein MD, Bowen RA, Henao-Tamayo M, Goodrich RP. A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model. Vaccines. 2021; 9(4):340. https://doi.org/10.3390/vaccines9040340
Chicago/Turabian StyleRagan, Izabela K., Lindsay M. Hartson, Taru S. Dutt, Andres Obregon-Henao, Rachel M. Maison, Paul Gordy, Amy Fox, Burton R. Karger, Shaun T. Cross, Marylee L. Kapuscinski, Sarah K. Cooper, Brendan K. Podell, Mark D. Stenglein, Richard A. Bowen, Marcela Henao-Tamayo, and Raymond P. Goodrich. 2021. "A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model" Vaccines 9, no. 4: 340. https://doi.org/10.3390/vaccines9040340